View More Recent Stories
-
Biohaven Pharma (BHVN) Falls 13% Following Update on Taldefgrobep Alfa Development Program for Spinal Muscular Atrophy and Obesity
-
Biohaven Pharma (BHVN) Provides Update on Taldefgrobep Alfa Development Program
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $75 at TD Cowen
-
Biohaven Pharmaceutical Holding (BHVN) PT Lowered to $66 at RBC Capital
-
Biohaven Pharma (BHVN) Misses Q3 EPS by 4c
-
BofA Securities Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Leerink Partners Reiterates Outperform Rating on Biohaven Pharmaceutical Holding (BHVN)
-
BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Baird Reiterates Outperform Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $63 at BofA Securities
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at JPMorgan
-
TD Cowen Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharma (BHVN) Prices 5.26M Share Offering at $47.50/sh
-
After-hours movers: IGM Biosciences, Biohaven Pharma, Acadia Realty Trust
-
Biohaven Pharma (BHVN) Announces Proposed $250M Share Offering
-
Biohaven Pharma (BHVN) Initiates Pivotal Trial of BHV-2100 for Treatment of Migraine
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Leerink Partners
-
H.C. Wainwright Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $62 at BofA Securities
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $68 at RBC Capital
-
TD Cowen Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
BTIG Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN), PT $59
-
Biohaven Pharmaceutical Holding (BHVN) PT Raised to $60 at Baird
-
Piper Sandler Reiterates Overweight Rating on Biohaven Pharmaceutical Holding (BHVN)
-
Biohaven Pharma (BHVN) Climbs 15% Following Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia
-
Biohaven Pharma (BHVN) Reports Positive Topline Results in Pivotal Study of Troriluzole in Spinocerebellar Ataxia
-
Jefferies Starts Biohaven Pharmaceutical Holding (BHVN) at Buy
-
Bernstein SocGen Group Starts Biohaven Pharmaceutical Holding (BHVN) at Outperform
-
Biohaven Pharma (BHVN) Misses Q2 EPS by 172c
-
RBC's biotech survey shows investors more bearish vs. last time
-
Morgan Stanley Starts Biohaven Pharmaceutical Holding (BHVN) at Overweight
-
2Q24 U.S. biotech earnings preview
-
Benitec Biopharma (BNTC) Announces Appointment of Kishen Mehta to its Board of Directors
-
TD Cowen Reiterates Buy Rating on Biohaven Pharmaceutical Holding (BHVN)
-
RBC Capital Reiterates Outperform Rating on Biohaven Pharmaceutical Holding (BHVN)

